Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 10/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456255 | 0.93 | BCL9 (0.48) | BCL9CTNNB1 | |
| SCHEMBL23456335 | 0.87 | BCL9 (0.49) | BCL9CTNNB1 | |
| SCHEMBL23456174 | 0.83 | BCL9 (0.51) | BCL9CTNNB1GPR119PDE4APDE4B | |
| SCHEMBL23456173 | 0.83 | BCL9 (0.51) | BCL9CTNNB1GPR119PDE4APDE4B | |
| SCHEMBL23456236 | 0.82 | GPR119 (0.40) | BCL9CTNNB1GPR119PDE4APDE4B | |
| SCHEMBL23456251 | 0.82 | CTNNB1 (0.47) | BCL9CTNNB1 | |
| SCHEMBL23456339 | 0.82 | BCL9 (0.49) | BCL9CTNNB1POLBGPR119ATR | |
| SCHEMBL23456344 | 0.81 | CTNNB1 (0.47) | BCL9CTNNB1 | |
| SCHEMBL19404226 | 0.81 | BCL9 (0.56) | BCL9CTNNB1 | |
| SCHEMBL30392124 | 0.81 | BCL9 (0.56) | BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | UNIVERSISITY OF UTAH RESEARCH FOUNDATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | UNITED STATES GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 6/4885POLB 3391/4885 |
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | BCL9 1/4885CTNNB1 6/4885POLB 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.